Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
← catalyst calendarSponsored by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
455actual
Sites
54
Countries
Canada, France, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-25 | actual | When the study began enrolling |
| Primary completion | 2023-11-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2020-12-01 | actual | When this record first appeared on the registry |
| Results posted | 2026-01-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-01-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-Resistant Prostate Cancer
Interventions
- Drug: [Lu-177]-PNT2002 — also filed as [Lu-177]-PSMA-I&T, LY4187525
- Drug: Abiraterone
- Drug: Enzalutamide
Primary outcome
what the primary-completion date above is the date OFRandomization Phase: Radiographic Progression-Free Survival (rPFS)
measured From the randomization date to the first documented progressive disease or death from any cause (up to 23 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-07-22 · 10.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-07-26 · 4.4 MB · SAP_001.pdf
Publications
- PMID 26795286 — cited as background
- PMID 39839782 — linked by the registry
- PMID 36735603 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed